Isarna Therapeutics is a leader in TGF-β therapeutics developing inhibitors intended to stimulate the human immune system to fight cancer and other diseases. The company is advancing a pipeline of novel oligonucleotides and combination modalities aimed at transcending clinical response and improving patient outcomes. Isarna announced it raised €5.5M (US$7.6M) in equity from current investors including AT NewTec, Global Asset Funds, and MIG Fonds. It also named Elizabeth Czerepak as Chief Financial Officer and Chief Business Officer to lead a new New York City office. Management described the hire and U.S. expansion as key strategic steps toward building the company’s presence in the global biotech industry. The company lists headquarters in Munich and a U.S. address on Madison Avenue in New York. Isarna Therapeutics is a Munich, Germany-based company that develops TGF-β inhibitors to fight cancer. Its core programs are oligonucleotide candidates designed to inhibit various isoforms of TGF-β, a pathway implicated in tumor immune evasion and proliferation. The company raised €13m (US$17.8m) in equity to advance this pipeline. Backers included new private investor AT NewTec and existing MIG-managed funds. Isarna is led by CEO Dr. Philippe Calais and intends to use the proceeds to push development of its oligonucleotide portfolio.

Total raised

$25M

Funding rounds

2

Latest round

Equity

Latest activity

Apr 2014